Blog
RSS FeedPosted by Michael Wonder on 19 Sep 2022
Pharmacists can now prescribe Paxlovid, but barriers persist
19 September 2022 - Recently, the FDA expanded access to COVID-19 treatment by authorising state-licensed pharmacists to prescribe Paxlovid to eligible ...
Posted by Michael Wonder on 17 Sep 2022
EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines
16 September 2022 - The EMA’s CHMP has recommended converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer’s ...
Posted by Michael Wonder on 17 Sep 2022
Take whatever COVID booster you can get, says head of EU drugs watchdog
14 September 2022 - People in Europe should take whatever COVID-19 booster is available to them in the coming months, ...
Posted by Michael Wonder on 17 Sep 2022
Swiss regulator gives green light to first drug to prevent Covid-19
16 September 2022 - Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis ...
Posted by Michael Wonder on 17 Sep 2022
CHMP adopts positive opinion to extend indication of Veklury (remdesivir) for the treatment of paediatric patients with COVID-19
16 September 2022 - If granted by the European Commission, Veklury will become the first and only authorised anti-viral treatment for ...
Posted by Michael Wonder on 14 Sep 2022
ATAGI update following COVID-19 meeting (7 September 2022)
14 September 2022 - An update from the Australian Technical Advisory Group on Immunisation following their meeting on 7 September 2022. ...
Posted by Michael Wonder on 13 Sep 2022
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorisation in the European Union for use as a booster for adults aged 18 and older
12 September 2022 - Nuvaxovid is now authorised in the EU for use in adults aged 18 and older as ...
Posted by Michael Wonder on 12 Sep 2022
Japan health ministry panel backs Pfizer and Moderna omicron boosters
12 September 2022 - Pfizer and Moderna’s COVID-19 vaccines targeting the omicron variant have won the backing of health experts ...
Posted by Michael Wonder on 12 Sep 2022
Vaxxinity initiates rolling submission for UB-612 COVID-19 vaccine with MHRA
12 September 2022 - Vaxxinity today announced that it has initiated a rolling submission to the MHRA in the United Kingdom ...
Posted by Michael Wonder on 12 Sep 2022
Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval
12 September 2022 - The EMA’s CHMP has recommended authorising an adapted bivalent vaccine targeting the Omicron sub-variants BA.4 and ...
Posted by Michael Wonder on 12 Sep 2022
ATAGI statement on use of the Moderna bivalent original/Omicron vaccine
12 September 2022 - A statement from the Australian Technical Advisory Group on Immunisation regarding COVID-19 Moderna Spikevax Bivalent Original/Omicron BA.1 ...
Posted by Michael Wonder on 12 Sep 2022
Australia's first bivalent COVID-19 vaccine to join rollout
12 September 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation on the ...
Posted by Michael Wonder on 12 Sep 2022
PHARMAC simplifies criteria for COVID-19 anti-viral treatments
12 September 2022 - PHARMAC has confirmed today that it is simplifying the access criteria for the three anti-viral treatments it ...
Posted by Michael Wonder on 09 Sep 2022
Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5
9 September 2022 - Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5. ...
Posted by Michael Wonder on 08 Sep 2022
COVID-19 vaccine safety report (8 August 2022)
8 September 2022 - To 4 September 2022, the TGA has received 699 reports which have been assessed as likely to ...